Skip to main content
  • Engineering any genome, at any site, in any way

  • At the forefront of a revolutionary field offering profound benefits to human health and society

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech


Caribou Biosciences Develops New Method to Profile CRISPR-Cas9 Gene Editing Outcomes

August 18, 2016
New method reveals that repair outcomes are nonrandom at Cas9 cut sites DNA repair outcomes can be manipulated via modulation of the cellular DNA repair machinery BERKELEY, CA – August 18, 2016 – Caribou Biosciences, Inc., a developer of...

Genus and Caribou Biosciences Announce Exclusive Collaboration for Leading CRISPR-Cas9 Gene Editing Technology in Livestock Species

May 18, 2016
BERKELEY, Calif. -- May 18, 2016 -- Genus plc (LSE: GNS) (“Genus”), a global pioneer in animal genetics, and Caribou Biosciences, Inc. (“Caribou”), a leader in the revolutionary field of CRISPR-Cas gene editing, are pleased to announce a...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...